Pristiq Indications/Uses

PRISTIQ, a selective serotonin and norepinephrine reuptake inhibitor (SNRI), is indicated for the treatment of major depressive disorder (MDD) [see Pharmacology: Pharmacodynamics: Clinical Studies under Actions and Initial Treatment of Major Depressive Disorder under Dosage & Administration]. The efficacy of PRISTIQ has been established in four 8-week, placebo-controlled studies of outpatients who met DSM-IV criteria for MDD.
A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, or a suicide attempt or suicidal ideation.
Pediatrics (<18 years of age): PRISTIQ is not indicated for use in children under the age of 18. Two placebo-controlled studies in 587 pediatric patients 7 to 17 years of age with MDD did not demonstrate efficacy.